diclofenac potassium liquid filled capsules / Generic mfg. - LARVOL DELTA

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy (clinicaltrials.gov) - P2 | N=20 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Diclofenac for the Treatment of Patients with Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy (clinicaltrials.gov) - P2 | N=20 | Not yet recruiting | Sponsor: Emory University

Metastases • New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • PD-L1

Nonopioid drugs for pain. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Immunology • Neuralgia • Osteoarthritis • Pain • Rheumatology

Comparison table: Some nonopioid analgesics for pain. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Pain

An Open-Label Study Evaluating the Pharmacokinetics and Safety of Diclofenac Potassium for Oral Solution for the Acute Treatment of MWA or MWoA in Pediatric Participants. (PubMed, Headache) - "Diclofenac potassium for OS exhibited a favorable pharmacokinetic and safety profile in 12- to 17-year-old patients with a diagnosis of episodic MWA or MWoA."

Clinical • Journal • PK/PD data • CNS Disorders • Migraine • Musculoskeletal Pain • Pain • Pediatrics

Effect of Diclofenac Potassium Premedication on Postendodontic Pain in Mandibular Molars with Symptomatic Irreversible Pulpitis: A Randomized Placebo-Controlled Double-Blind Trial. (PubMed, J Endod) - "Premedication by a single, oral dose of 50 mg DFK could be effective in reducing postendodontic pain at 48 hours after 1-visit endodontic treatment in mandibular molars with symptomatic irreversible pulpitis."

Clinical • Journal • Dental Disorders • Immunology • Pain

Depomed reports first quarter 2015 financial results (PRNewswire) - " '...With NUCYNTA, we are now expecting 2015 total product sales of $310-$335 million, which is nearly triple our 2014 product sales and over five times 2013 product sales.'...First quarter 2015 net sales (for Gralise) were $17.3 million, up 59% compared to $10.9 million in first quarter 2014....First quarter 2015 net sales (for Cambia) were $5.4 million, up 16% compared to $4.6 million in first quarter 2014....First quarter 2015 net sales of $3.2 million (for Lazanda), up 369% compared to $680,000 in first quarter 2014....First quarter 2015 net sales (for Zipsor) of $5.8 million, up 9% compared to $5.3 million in first quarter 2014."

Sales • Sales projection • Pain

Three newly approved analgesics: an update (Anesth Prog) - "Tapentadol immediate-release is a both a mu-opioid agonist and a norepinephrine reuptake inhibitor, and is indicated for the treatment of moderate to severe pain. Diclofenac potassium soft gelatin capsules are a novel formulation of diclofenac potassium, which is a nonsteroidal anti-inflammatory drug (NSAID), and its putative mechanism of action is through inhibition of cyclooxygenase enzymes....Liposomal bupivacaine is a new formulation of bupivacaine intended for single-dose infiltration at the surgical site for postoperative analgesia."

Review • Pain

Depomed files patent infringement lawsuit against Zipsor ANDA filer (PRNewswire) - "Depomed...announced it has filed a patent infringement lawsuit in the United States District Court for the District of New Jersey against Banner Pharmacaps Inc. and Watson Laboratories, Inc. Banner Pharmacaps has filed an Abbreviated New Drug Application (ANDA) with the FDA to market generic Zipsor® (diclofenac potassium) 25mg capsules and has granted to Watson Laboratories exclusive rights to the proposed generic product."

Corporate lawsuit • Pain

The 24-h progression of menstrual pain in women with primary dysmenorrhea when given diclofenac potassium: a randomized, double-blinded, placebo-controlled crossover study (Arch Gynecol Obstet) - P=NA, N=NA; “Menstrual pain intensity was significantly reduced after taking the first capsule of diclofenac, and remained consistently lower (P < 0.0001), compared with initial pain intensity, in the morning (before treatment), throughout the day, evening, and into the next morning. Also, women rated their pain intensity as significantly lower (P < 0.001) at each time point across the 24-h time interval of the cycle when receiving diclofenac compared with the cycle when they received placebo.”

Clinical data • Pain

Loxoprofen Sodium Versus Diclofenac Potassium for Post-Dental Extraction Pain Relief: A Randomized, Triple-Blind, Clinical Trial. (PubMed, Dent J (Basel)) - "However, both groups demonstrated comparable (p > 0.05) post-operative pain relief over the other aforementioned allocated time intervals. In conclusion, the diclofenac potassium group had slightly better control over post-operative pain than the group receiving loxoprofen sodium."

Clinical • Journal

IM ketorolac vs diclofenac potassium powder for oral solution for the acute treatment of severe migraine: a randomized controlled trial. (PubMed, Neurol Sci) - P4; "In treatment of refractory migraine headache, CAMBIA® may provide similar benefits as IM ketorolac without increasing the risk of treatment failure, major bleeding, or cardiovascular events. However, larger studies are needed to confirm this finding."

Clinical • Journal • Review

Clay nanotubes as a novel multifunctional excipient for the development of directly compressible diclofenac potassium tablets in a SeDeM driven QbD environment. (PubMed, Eur J Pharm Sci) - "A shelf-life of ~34 months was found upon long-term stability testing of the optimized formulation. This study demonstrates that this novel and economically viable clay material has a strong potential for commercial use in tableting of drug by direct compression."

Journal

Assertio Therapeutics Announces Strong Second-Quarter 2019 Results (GlobeNewswire, Assertio Therapeutics, Inc.) - Neurology Franchise Net Sales: Gralise net sales in the second quarter were $17.8 million, primarily due to favorable year-over-year gross to net reflecting payor mix. In August, the Company executed an agreement that provides expanded access for Gralise through new coverage with one of the top three Medicare Part-D insurers, representing more than 6 million lives. In the second quarter, Zipsor net sales were $1.5 million, adversely impacted by short-dated product sales returns; however,...

Clinical • Commercial • Reimbursement

Oral Diclofenac Potassium Versus Hyoscine-N-Butyl Bromide In Reducing Pain Perception During Office Hysteroscopy: A Randomized Double-Blind Placebo-Controlled Trial. (PubMed, J Minim Invasive Gynecol) - P2/3; "Oral diclofenac potassium administration 1 hour prior to diagnostic OH reduces the procedure pain with subsequent easier and shorter OH duration. Oral HBB is less effective than diclofenac potassium with more adverse effects. The trial is registered at Clinicaltrials.gov on March 21, 2016 with number NCT02714699 and available at:https://clinicaltrials.gov/ct2/show/NCT02714699?term=NCT02714699&rank=1."

Clinical • Journal

Kounis Syndrome Induced by Oral Intake of Diclofenac Potassium. (PubMed, Iran J Allergy Asthma Immunol) - "The patient was discharged on the second day, and he was doing well on the control visit 2 weeks later. All allergic reactions may trigger an ACS so physicians should be aware of KS and always keep that unique clinical entity in mind to recognize it promptly and direct the therapy at suppressing the allergic reaction and improving the coronary circulation simultaneously when encountering a patient with symptoms suggesting an allergic reaction and a concomitant ACS."

Journal

Oral Diclofenac Potassium Versus Intravenous Acetaminophen in Acute, Isolated, Closed-Limb Trauma. (PubMed, Adv Emerg Nurs J) - "No significant change was observed between the 2 groups (p = 0.11). In this study, both drugs could decrease the pain score effectively and safely in isolated limb trauma."

Journal